A stable pharmaceutical composition
By adding sodium metabisulfite to the edaravone drug composition and controlling its content, the problems of drug composition stability and impurity control were solved, the treatment time window was extended, and the safety of medication was improved.
CN119896666BActive Publication Date: 2026-07-03SIMCERE PHARMA CO LTD +1
3 Cites 0 Cited by
Patent Information
- Application Number
- CN202510098727.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-08-17
- Filing Date
- 2021-08-16
- Publication Date
- 2026-07-03
- Estimated Expiration
- 2041-08-16
AI Technical Summary
Technical Problem
Existing edaravone drug compositions have problems such as short therapeutic window, poor stability, difficulty in controlling impurities, and low drug safety when used to treat stroke.
Method used
By adding sodium metabisulfite to the pharmaceutical composition and controlling its content within the range of 0.95–1.05 mg/mL, combined with edaravone, dextroborneol, and a solubilizer, a stable pharmaceutical composition is formed, thereby controlling the formation of impurities SCR-756 and SCR-757.
Benefits of technology
It effectively controls the impurity content in the drug composition, prolongs stability, and improves the therapeutic window and drug safety.
✦ Generated by Eureka AI based on patent content.
Abstract
The application belongs to the technical field of medicine, and discloses a stable pharmaceutical composition. The pharmaceutical composition with active ingredients of edaravone and dextrocamphor can unexpectedly control the content of specific impurities SCR-756 and impurities SCR-757, and solves the problems of difficult control of impurities and product quality, short storage period and the like from the source.
Need to check novelty before this filing date? Find Prior Art